TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03948035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: i.v. infusion. Induction 6 cycles: 10mg/kg BW D1,8,15,22 of cycle 1 and 2, D1,15 of cycles 3-6. Consolidation 4 cycles: 10mg/kg BW D1,15 of cycle 1-4. Maintenance 28-day cycles: 20mg/kg BW D1 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: i.v. infusion. Induction 6 cycles: 20 mg/m² on D1 and 2 of cycle 1, 36 mg/m² on D8, 9, 15, 16 of cycle 1, 36 mg/m² on D1,2,8,9,15,16 of cycle 2-6; Consolidation 4 cycles: 36 mg/m² on days 1, 2, 8, 9, 15, 16 of cycles 1-4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib
Description: i.v. infusion. Induction 6 cycles: 20 mg/m² on D1 and 2 of cycle 1, 36 mg/m² on D8, 9, 15, 16 of cycle 1, 36 mg/m² on D1,2,8,9,15,16 of cycle 2-6; Consolidation 4 cycles: 36 mg/m² on days 1, 2, 8, 9, 15, 16 of cycles 1-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: hard capsule for oral use. Induction 6 cycles: 25mg D1-21 of cycle 1-6. Consolidation 4 cycles: 15mg D1-21 of cycle 1, 25mg D1-21 ov cycle 2-4. Maintenance 28-day cycles: 10mg D1-28 of cycle 1,2,3, 15mg D1-28 of cycle 4 and all subsequent cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: hard capsule for oral use. Induction 6 cycles: 25mg D1-21 of cycle 1-6. Consolidation 4 cycles: 15mg D1-21 of cycle 1, 25mg D1-21 ov cycle 2-4. Maintenance 28-day cycles: 10mg D1-28 of cycle 1,2,3, 15mg D1-28 of cycle 4 and all subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: orally and i.v. IN ARM A:Induction 6 cycles: 28mg p.o. and 8mg i.v. D1,8,15,22 of cycles 1-2 and D1,15 of cycles 3-6, 40mg p.o. D8,22 of cycle 3-6. Consolidation 4 cycles: 28mg p.o. and 8mg i.v. D1,15 of cycle 1-4 and 20mg p.o. D8,22 of cycle 1-4. IN ARM B: Induction 6 cycles: 40mg p.o. D1,8,15,22 of cycles 1-6. Consolidation 4 cycles: 20mg p.o. D1,8,15, 22 of cycle 1-4 .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: orally and i.v. IN ARM A:Induction 6 cycles: 28mg p.o. and 8mg i.v. D1,8,15,22 of cycles 1-2 and D1,15 of cycles 3-6, 40mg p.o. D8,22 of cycle 3-6. Consolidation 4 cycles: 28mg p.o. and 8mg i.v. D1,15 of cycle 1-4 and 20mg p.o. D8,22 of cycle 1-4. IN ARM B: Induction 6 cycles: 40mg p.o. D1,8,15,22 of cycles 1-6. Consolidation 4 cycles: 20mg p.o. D1,8,15, 22 of cycle 1-4 .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplant
Description: autologous stem cell transplant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: autologous stem cell transplant
Description: autologous stem cell transplant
Study: NCT02901275

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Within-subject test of blinded study medications
Description: Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Within-subject test of blinded study medications
Description: Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Within-subject test of blinded study medications
Description: Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Within-subject test of blinded study medications
Description: Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Within-subject test of blinded study medications
Description: Within-subject double-blind, double-dummy, study design wherein all participants received all doses in 8-hour outpatient sessions. Primary outcomes assessed during 8-hour outpatient sessions and included laboratory pain testing, subjective reports of drug effects, and cognitive performance, evaluated as a function of study medication condition.
Study: NCT03148457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)
Description: Early treatment will be started within 48 hours after symptom onset (minor and moderate ischaemic stroke) or at day 6 + 1 day after symptom onset (major ischaemic stroke)

Intervention type: DRUG
Group type: OTHER
Intervention: Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)
Description: Patients in the control arm will receive late treatment as per current recommendations (i.e. minor ischaemic stroke after day 3 + 1 day, moderate ischaemic stroke after day 6 + 1 day and major ischaemic stroke after day 12 + 2 day).
Study: NCT01652326

Intervention type: DRUG
Intervention: Diazepam
Study: NCT03122613

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: 3g of Curcumin per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3g of Curcumin Placebo per day
Study: NCT03373058

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy
Description: HIPEC is performed as postoperative chemotherapy after cytoreductive surgery for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 48h after cytoreductive surgery: Paclitaxel 175 mg/m\^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The HIPEC regimens are Docetaxel 75 mg/m\^2 and cisplatin 75 mg/m\^2, respectively, 43°C, 90min.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cytoreductive surgery
Description: Cytoreductive surgery (CRS) is performed when Faggoti value is less than 6 via laparoscopic exploration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cytoreductive surgery
Description: Cytoreductive surgery (CRS) is performed when Faggoti value is less than 6 via laparoscopic exploration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant chemotherapy
Description: Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy
Description: Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 2 cycles in experimental group.~Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m\^2 IV\>3 hour+ carboplatin AUC = 5-6 IV\>1 hour, every 3 weeks for 3 cycles in control group.
Study: NCT03181503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD14152 Dose A
Description: 3 subcutaneous injections (every 4 weeks during the 12-week treatment period)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD14152 placebo
Description: 3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
Study: NCT04056273

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guide sheath group
Description: After the lesion was found by rEBUS, insert the rEBUS into a guide sheath and re-locate the lesion. Fix the guide sheath at that position and perform transbronchial biopsy and brushing through the guide sheath.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional group
Description: After the lesion was found by rEBUS, mark the location and depth. Insert the biopsy forceps and cytology brush to the marked depth of that bronchiole to perform biopsy and brushing.
Study: NCT03489005

Intervention type: DRUG
Group type: OTHER
Intervention: BIA 5-1058
Description: Subjects will receive BIA 5-1058 tablets (containing 100 mg) as single, oral doses 30 minutes after the start of a moderate mealas follows:~* 400 mg BIA 5 1058, as 4 × 100 mg tablets and 8 placebo tablets~* 1200 mg BIA 5 1058, as 12 × 100 mg tablets

Intervention type: DRUG
Group type: OTHER
Intervention: BIA 5-1058
Description: Subjects will receive BIA 5-1058 tablets (containing 100 mg) as single, oral doses 30 minutes after the start of a moderate mealas follows:~* 400 mg BIA 5 1058, as 4 × 100 mg tablets and 8 placebo tablets~* 1200 mg BIA 5 1058, as 12 × 100 mg tablets

Intervention type: DRUG
Group type: OTHER
Intervention: BIA 5-1058
Description: Subjects will receive BIA 5-1058 tablets (containing 100 mg) as single, oral doses 30 minutes after the start of a moderate mealas follows:~* 400 mg BIA 5 1058, as 4 × 100 mg tablets and 8 placebo tablets~* 1200 mg BIA 5 1058, as 12 × 100 mg tablets

Intervention type: DRUG
Group type: OTHER
Intervention: BIA 5-1058
Description: Subjects will receive BIA 5-1058 tablets (containing 100 mg) as single, oral doses 30 minutes after the start of a moderate mealas follows:~* 400 mg BIA 5 1058, as 4 × 100 mg tablets and 8 placebo tablets~* 1200 mg BIA 5 1058, as 12 × 100 mg tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Oral Tablet
Description: Matching placebo tablets administered as follows:~- placebo, as 12 × 0-mg tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Oral Tablet
Description: Matching placebo tablets administered as follows:~- placebo, as 12 × 0-mg tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Oral Tablet
Description: Matching placebo tablets administered as follows:~- placebo, as 12 × 0-mg tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Oral Tablet
Description: Matching placebo tablets administered as follows:~- placebo, as 12 × 0-mg tablets

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin 400 mg
Description: Administered as follows:~- 400 mg moxifloxacin, as 1 × 400-mg tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin 400 mg
Description: Administered as follows:~- 400 mg moxifloxacin, as 1 × 400-mg tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin 400 mg
Description: Administered as follows:~- 400 mg moxifloxacin, as 1 × 400-mg tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Moxifloxacin 400 mg
Description: Administered as follows:~- 400 mg moxifloxacin, as 1 × 400-mg tablet
Study: NCT03957135

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic distal pancreatectomy
Description: Laparoscopic resection of the diseased portion of the pancreas for treatment of pancreatic cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open distal pancreatectomy
Description: Open resection of the diseased portion of the pancreas for treatment of pancreatic cancer
Study: NCT01015222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting dose of 50 mg daily PO for 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Starting dose 5 mg/kg IV Day 1 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Starting dose 40 mg/m2 IV Day 1, 8 and 15
Study: NCT03432949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone plus Radium-223
Description: Dexamethasone will be administered as 0.5 mg capsules by mouth per day during the duration of the Radium-223 treatment.
Study: NCT01424059

Intervention type: OTHER
Intervention: WEDQ-B (questionnaire)
Description: Questionnaires are answered after delivery; within 48 hours and after five weeks
Study: NCT01987830

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI-PET
Description: * \[11C\] temozolomide for PET scan and a contrast dye for the MRI scan~* Drawing blood to assess the radioactivity of \[11C\] temozolomide

Intervention type: DEVICE
Group type: OTHER
Intervention: TMZ-PET
Description: The PET scan will take approximately 90 minutes. You will receive one injection of \[11C\] temozolomide. Following the injection of the radioactive substance, blood samples will be taken from the second IV line.
Study: NCT02337712

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: q.d. RT
Description: 65 Gy in 26 fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: b.i.d.RT
Description: 45 Gy in 30 fractions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide and cisplatin
Description: etoposide and cisplatin concurrent with radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide and cisplatin
Description: etoposide and cisplatin concurrent with radiotherapy
Study: NCT03770013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: bupivacaine 0.25% a total volume of 40 ml (20 ml each side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: bupivacaine 0.25% a total volume of 40 ml (20 ml each side

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacaine
Description: bupivacaine 0.25% a total volume of 40 ml (20 ml each side

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.5 mcg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine
Description: 1ug/kg clonidine
Study: NCT04047134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Action Observation Treatrment
Description: Participants will be asked to carefully observe the videos showing different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes, totally lasting 12 min/video. At the end of each motor act presentation, participants will be asked to execute with the affected hand the observed motor sequence for 2 minutes (20 minutes/session). 10 daily actions will be recorded. Each video will be presented to participants twice a day, in order to complexity as judged by the experimenter. Only 1 typology of motor task per day for each condition, starting from the easiest and ending with the most complex action throughout 15 sessions spread on 5 weeks (3 sessions/week). Tasks will be based on some relevant activities of daily living belonging to at least one between feeding, self-care or external actions category on the affected side. Each session will last about 15 minutes and will be repeated twice a day, at least 60 minutes apart.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation of videos with Non Motor contents
Description: Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
Study: NCT03366324

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Second generation CAR-T cells
Description: Patients receive CD19 CAR-T cells transduced with a lentiviral vector on days 0, 1, and 2.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematological stem cell transplantation
Description: Patients receive hematological stem cell transplantations within 3 months after they achieve MRD- remissions after CAR-T therapies.
Study: NCT03211923

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial magnetic stimulation (TMS)
Description: Single pulse, monophasic transcranial magnetic stimulation

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial magnetic stimulation (TMS)
Description: Single pulse, monophasic transcranial magnetic stimulation

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial magnetic stimulation (TMS)
Description: Single pulse, monophasic transcranial magnetic stimulation
Study: NCT02662400

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MNCs
Description: 200 - 300 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months
Study: NCT01953835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586184 standard formulation
Description: GSK2586184 standard formulation is a white film coated round biconvex 200 mg oral tablet. For cohort A, it is to be administered at 400 mg (200 mg x 2 tablets) twice daily from Day 6 to Day 14. For cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose after standard breakfast either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day wash out period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586184 standard formulation
Description: GSK2586184 standard formulation is a white film coated round biconvex 200 mg oral tablet. For cohort A, it is to be administered at 400 mg (200 mg x 2 tablets) twice daily from Day 6 to Day 14. For cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose after standard breakfast either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day wash out period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin 10 mg oral tablet is peach-coloured, oval-shaped tablets. It is to be administered orally as a single dose of 10 mg tablet on the mornings of Day 1 and Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2586184 new formulation
Description: GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
Study: NCT03714646

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: beta glucan and resistant starch
Description: 12g per day the day before the CID Resistant starch 7.5 g

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: isocaloric maltodextrin before the CID

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: beta gluten
Description: 12 g beta gluten there day before the CID
Study: NCT02255318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taurolock

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00897962

Intervention type: OTHER
Intervention: Healthy Controls
Description: One blood draw (2 teaspoons)

Intervention type: OTHER
Intervention: Metastatic Breast Cancer
Description: Blood samples will be drawn every 3 months, for up to 18 months.

Intervention type: OTHER
Intervention: Non-cancer medical illness
Description: One blood draw (2 teaspoons)
Study: NCT01899716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study: NCT02202044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravesical BCG and EMDA/MMC
Description: Patients are assigned one course of treatment per week for 6 weeks with sequential 'Intravesical instillation of sequential Bacillus Calmette-Guérin (BCG) and Electromotive Drug Administration /Mitomycin-C
Study: NCT00549913

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoFuse
Description: immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse) combined with MasterGraft Resorbable Ceramic Granules in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoFuse
Description: immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse) combined with MasterGraft Resorbable Ceramic Granules in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeoFuse
Description: immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse) combined with MasterGraft Resorbable Ceramic Granules in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterolateral spinal fusion with instrumentation
Description: autograft in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterolateral spinal fusion with instrumentation
Description: autograft in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: posterolateral spinal fusion with instrumentation
Description: autograft in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
Study: NCT03707119

Intervention type: OTHER
Intervention: Educational programme
Description: the health professional students were undergone to Student 4 Best Evidence blog, as a specific educational programme to learn EBP competencies.
Study: NCT00437827

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Star*D algorithm
Description: Standard of care based upon the therapies selected in the Star\*D study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rEEG-guided therapy
Description: An rEEG report is based upon a process that utilizes a patient's drug-free QEEG to predict successful treatment strategies.